AGRX Agile Therapeutics Inc.

1.38
-0.03  -2%
Previous Close 1.41
Open 1.4
Price To Book 2.94
Market Cap 59635849
Shares 43,214,383
Volume 220,630
Short Ratio
Av. Daily Volume 672,566

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Further CRL issued December 22, 2017. Resubmission due 2Q 2019.
Twirla
Contraceptive patch

Latest News

  1. Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK
  2. Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress
  3. AGRX: Numerous Catalysts in 2019…
  4. Agile Therapeutics: 4Q Earnings Snapshot
  5. Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  6. Agile Therapeutics to Present at Upcoming Investor Conferences
  7. Agile Therapeutics Announces $7.8 Million Private Placement
  8. AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19
  9. Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
  10. Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference
  11. AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19…
  12. The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
  13. Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
  14. Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth
  15. Agile Therapeutics to Present at Biotech Showcase 2019
  16. Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®
  17. Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic?
  18. AGRX: Awaiting Details of Adhesion Study for Twirla®…
  19. Agile Therapeutics Reports Third Quarter 2018 Financial Results